Intangiriro
Umubyibuho ukabije ukomeje kuba imwe mu mbogamizi zikomeye ku buzima ku isi, zifitanye isano n'indwara zidakira nka diyabete, indwara z'umutima n'imitsi, na kanseri zimwe. Mugihe impinduka zubuzima zikomeza kuba urufatiro rwo gucunga ibiro, abantu benshi bakeneye inkunga yinyongera kugirango bagabanye ibiro bifatika kandi birambye. Vuba aha, ubuvuzi bushya bwa incretin bushingiye ku bushakashatsi bwabyibushye. Muri byo, Retatrutid yakuruye cyane uburyo bwihariye hamwe nibisubizo byikigereranyo. Iyi ngingo izasesengura ibyavuye mu mavuriro agezweho kugira ngo harebwe uburyo Retatrutid ikora neza mu kuvura umubyibuho ukabije, itanga ubumenyi ku ruhare rwayo mu gihe kizaza cyo gucunga ibiro.
Gusobanukirwa Retatrutid hamwe nuburyo bukoreshwa
Retatrutid nigisekuru kizaza-reseptor agonist yibasira GLP-1 (glucagon imeze nka peptide-1) , GIP (glucose iterwa na insulineotropique polypeptide) , hamwe na reseptor ya glucagon . Ubu buryo '' butatu agonist 'butandukanya Retatrutid nibiyobyabwenge byambere nka semaglutide, byibasira GLP-1 gusa. Mugukora icyarimwe gukora reseptors eshatu, Retatrutid igira ingaruka kumikorere yo kurya, gukoresha ingufu, hamwe na glucose metabolism mugari. Iki gishushanyo ntigamije guhagarika ubushake bwo kurya gusa ahubwo no kongera umuriro wa calorie, bigatuma bishoboka cyane muburyo bwo kuvura umubyibuho ukabije.
Bitandukanye n'imiti isanzwe, uburyo bwa Retatrutid butuma ibiryo bigabanuka ndetse no kongera ingufu zikoreshwa , bigatanga ingaruka ebyiri. Iyi nzira ebyiri irashobora gusobanura impamvu ibisubizo byubuvuzi hakiri kare byerekana ibiro byimbitse kandi biramba ugereranije nindi miti iboneka ubu.
Ikigeragezo Cyibanze Cyibisubizo bya Retatrutid mubyibushye
Bumwe mu bushakashatsi bwavuzwe cyane kuri Retatrutid ni ikizamini cya 2 cy’amavuriro cyasohotse mu 2023, cyandikamo abantu bakuru bafite umubyibuho ukabije cyangwa umubyibuho ukabije nta diyabete. Abitabiriye amahugurwa bahawe dosiye zitandukanye za Retatrutid ugereranije na placebo. Ibisubizo byerekanye ko nyuma yibyumweru 48:
Abitabiriye igipimo kinini cya Retatrutid bagabanutse kugera kuri 24% byuburemere bwumubiri.
Ndetse no ku kigero giciriritse, kugabanya ibiro byarushije cyane umwanya wawo kandi ugereranije neza namakuru yikigereranyo ya semaglutide.
Iterambere ryagaragaye no mu bimenyetso byubuzima bwa metabolike, harimo glucose yamaraso, umuvuduko wamaraso, hamwe na lipide.
| Ikigeragezo Ikiringo |
cya Placebo Itsinda |
Moderate-Dose Retatrutid |
Yinshi-Dose Retatrutid |
| Ibyumweru 24 |
Kugabanuka ibiro 2% |
Kugabanuka ibiro 12% |
Kugabanuka ibiro 18% |
| Ibyumweru 48 |
Kugabanuka ibiro 3% |
Kugabanuka ibiro 17% |
Kugabanuka ibiro 24% |
Ibisubizo byerekana ko Retatrutid ishobora kugera ku gutakaza ibiro byegereye urwego rwo kubaga ibibari , hatabayeho kwibasirwa no kubaga.
Kugereranya Retatrutid hamwe nubuvuzi buriho
Iyo usuzumye imikorere ya Retatrutid, ni ngombwa kuyigereranya nubundi buvuzi bwaganiriweho:
| Ibiyobyabwenge |
Urwego |
Ugereranije Kugabanuka Ibiro Mubigeragezo |
Igihe cy'iburanisha |
| Semaglutid |
GLP-1 agonist |
15% mu byumweru 68 |
Kubungabunga igihe kirekire birakenewe |
| Tirzepatid |
GLP-1 + GIP dual agonist |
20% mu byumweru 72 |
Gukora neza ariko gutangira buhoro |
| Retatrutid |
GLP-1 + GIP + Glucagon triple agonist |
Kugera kuri 24% mu byumweru 48 |
Igisubizo cyihuse kandi cyimbitse |
Ugereranije na semaglutide na tirzepatide, Retatrutid yerekana gutakaza ibiro byihuse hamwe nubushobozi bwinyungu ndende. Mugihe hakiri kare gutangaza ko iruta iyindi, uburyo bwayo butatu bwakira busa nkaho butanga umurongo.
Umutekano n'ingaruka Zigaragara Mubigeragezo bya Clinical
Kimwe nindi miti ishingiye kuri incretin, ingaruka za gastrointestinal nizo zagaragaye cyane hamwe na Retatrutid. Muri byo harimo isesemi, kuruka, no gucibwamo, cyane cyane mu byumweru bya mbere byo kwivuza. Nyamara, ibimenyetso byinshi byagabanutse mugihe uko abitabiriye bahinduye. Icy'ingenzi, ni ibintu bikomeye byabaye bibi, kandi abashinzwe iperereza bavuze ko muri rusange Retatrutid yihanganirwa.
Amakuru yumutekano maremare aracyakusanywa, ariko umwirondoro muto-wo hagati urashimishije. Ugereranije na semaglutide na tirzepatide, Retatrutid ntabwo isa nkaho itangiza ibyiciro bishya byingaruka ariko bizakenera gukurikirana ingaruka zishobora kubaho nka pancreatite cyangwa ibibazo bya tiroyide, bihuye niki cyiciro cyimiti.
Ibyiza bya Retatrutid Kurenza Ubundi buvuzi
Inyungu nyinshi zidasanzwe zigaragara mugihe usuzumye ubushobozi bwa Retatrutid:
Ingaruka zikomeye zo kugabanya ibiro - Ibimenyetso byambere byerekana ijanisha ryinshi ryo kugabanya ibiro ugereranije nubuvuzi busanzwe.
Iterambere rya metabolike - Kurenza ibiro, Retatrutid yazamuye cholesterol, umuvuduko wamaraso, hamwe na insuline.
Ingaruka ebyiri ku gufata no gukoresha - Ubushobozi bwayo bwo gukoresha ingufu zishobora gutuma kubungabunga ibiro bishoboka.
Gutangira byihuse ibisubizo - Kugabanuka gukomeye byagaragaye nkibyumweru 24, bishobora guteza imbere ubushake bwabarwayi no kubahiriza.
Ihuriro ryinyungu rishobora gushyira Retatrutid nkumurongo wambere wubuvuzi bwa farumasi niba amakuru maremare akomeje kuba umwe.
Imipaka n'ibibazo bisigaye bivuye mubigeragezo bya Clinical
Nubwo ibisubizo bitangaje, imbogamizi nyinshi nibibazo bitashubijwe bisigaye:
Igihe cyibigeragezo : Ubushakashatsi bwinshi ntabwo bwarenze ibyumweru 48, bityo igihe cyo kugabanya ibiro ntikiramenyekana.
Umutekano muremure : Mugihe amakuru yambere yerekana kwihanganira, ingaruka zijyanye no gukoresha karande zigomba gusobanurwa.
Igiciro no kugerwaho : Niba igiciro kimwe nindi miti ya GLP-1, ubushobozi burashobora kugabanya kwakirwa kwinshi.
Imikorere nyayo-yisi : Igeragezwa rya Clinical igenamigambi itandukanye nukuri kwisi, kandi nibikorwa bifatika bikenera kwemezwa.
Izi mbogamizi zirashimangira akamaro ko kwiga icyiciro cya 3 gikomeje hamwe nogukurikirana nyuma yamasoko.
Icyerekezo kizaza: Retatrutid ishobora kongera kuvura umubyibuho ukabije?
Niba icyiciro cya 3 nubushakashatsi bwigihe kirekire byemeza imikorere ya Retatrutid numutekano, birashobora guhindura cyane imiterere yo kuvura umubyibuho ukabije. Hamwe no kugabanya ibiro byegereje kubagwa, Retatrutid irashobora guhinduka uburyo butemewe bwo gutera kubantu badashobora cyangwa badashaka kubagwa ibibari. Inyungu nini ya metabolike yerekana kandi uburyo bushoboka bwo gukumira cyangwa gucunga ibintu bifitanye isano nka diyabete yo mu bwoko bwa 2 n'indwara z'umutima.
Umwanzuro
Igeragezwa rya Clinical data kuri Retatrutid ryerekana ubushobozi bwarwo nkimwe mu miti ifata imiti igabanya umubyibuho ukabije kugeza ubu. Muguhuza triple reseptor agonism hamwe no kugabanya ibiro, inyungu za metabolike, hamwe ningaruka zishobora kwihanganira, Retatrutid itanga ibyiringiro byigihe gishya mugucunga ibiro. Mugihe ibibazo bikomeje kuba umutekano muremure, ikiguzi, no kugerwaho, ibimenyetso byambere biratanga ikizere. Kugeza ubu, Retatrutid yerekana impinduka zishobora guhindura umukino mukuvura umubyibuho ukabije mugihe hagitegerejwe kwemezwa nubushakashatsi burimo gukorwa.
Ibibazo
1. Kugabanuka ibiro bingana iki hamwe na Retatrutid?
Igeragezwa rya Clinical data ryerekana kugabanya ibiro bigera kuri 24% byuburemere bwumubiri nyuma yibyumweru 48, bikaba birenze imiti myinshi ihari.
2. Retatrutid ifite umutekano kugirango ikoreshwe igihe kirekire?
Ubushakashatsi bugezweho bwerekana ko muri rusange ari umutekano kandi wihanganirwa, ariko amakuru maremare aracyakenewe kugirango hemezwe umutekano urenze umwaka.
3. Retatrutid igereranya ite na semaglutide cyangwa tirzepatide?
Retatrutid yerekana imbaraga nyinshi zo kugabanya ibiro hamwe nibisubizo byihuse, bitewe nuburyo bwayo butatu.
4. Ni izihe ngaruka zifitanye isano na Retatrutid?
Ingaruka zikunze kugaragara ni gastrointestinal, harimo isesemi na diarrhea, mubisanzwe bigabanuka mugihe.
5. Retatrutid izaboneka ryari?
Biracyakurikiranwa n’amavuriro. Kuboneka kwinshi bizaterwa n'ibisubizo by'icyiciro cya 3 gikomeje no kwemezwa n'amategeko.
